动物造模,哮喘小鼠,气道炎症 z-bio 2021-10-15 197

　　Objective: To discuss the effect of miR-20b on airway inflammation in asthmatic mice.

　　Method: BALB/c mice were randomly divided into normal control group, asthma group, asthma + miR-20b mimic treatment group, asthma + miR-20b mimic control treatment group. Ovalbumin (OVA) sensitizes and arouses the constructed asthma model mice. The miR-20b mimic and its control are administered by nasal drops. On the 49th day of the experimental procedure, the total number and classification of cells in the bronchoalveolar lavage fluid (BALF) were detected. The HE staining of the lung tissue was stopped to observe the pathological changes, and the concentration of vascular endothelial growth factor (VEGF) in BALF was detected by ELISA.

　　Results: After asthmatic mice were treated with miR-20b mimics, the total number of cells and the differential counts of neutrophils and eosinophils in BALF were significantly reduced (P<0.01), and the thickening of airway mucosa was reduced, and the airway cavity The secretion of internal mucus and the infiltration of inflammatory cells around the bronchi are reduced. Compared with the content of VEGF in BALF of asthma group of 28.55±3.42 pg/mL, the content of asthma+miR-20b mimic treatment group was 18.19±3.67 pg/mL significantly lower (P<0.01).

　　Conclusion: miR-20b has an inhibitory effect on airway inflammation in asthmatic mice. This effect may be mediated by reducing the expression of VEGF.